FDA warns Neogen, manufacturer after HYCOAT horse infections

FDA has escalated its response to the HYCOAT contamination case, issuing warning letters to Neogen Corporation and Sciarra Aeromed after an investigation tied the sterile veterinary product to serious fungal infections in nearly 100 horses and at least 20 euthanizations. The product, Neogen Vet HYCOAT hyaluronate sodium sterile solution, had already been pulled in a voluntary nationwide recall on January 28, 2026, after reports of adverse events in horses. FDA says the contamination incident is the deadliest quality defect ever linked to an FDA-regulated veterinary medical product in horses. (fda.gov)

HYCOAT is marketed as a wound management product for dogs, cats, and horses, not as an intra-articular injection. But Neogen’s recall notice acknowledged that the company had received adverse event reports in horses after intra-articular administration, which it said was inconsistent with the labeled intended use. Out of caution, Neogen recalled all lots within expiry, including 2 mL/20 mg vials, while noting the initial contamination signal involved certain 10 mL/50 mg vials. (investors.neogen.com)

The regulatory focus now appears to be on both product contamination and manufacturing controls. Public FDA materials confirm that warning letters are the agency’s principal tool for seeking prompt voluntary compliance after significant violations, though the letters themselves do not necessarily represent the final regulatory status of a case. As of September 30, 2026, FDA’s public CVM warning letter index was available, but the specific HYCOAT-related letters were not easily surfaced in search results, suggesting additional documentation may still be pending or not yet indexed in a way that is easy to retrieve publicly. That’s an inference based on the FDA database and search results, not a confirmed agency statement. (fda.gov)

Industry coverage has added important detail. Reports citing FDA said the product was contaminated with five fungal species and connected the event to nearly 100 equine infections, with at least 20 horses ultimately euthanized after treatment failed. Those reports also said FDA considers this the largest number of deaths in any animal species linked to microbiological contamination of an FDA-regulated product labeled as sterile. While secondary coverage should be read cautiously, that framing is consistent across multiple trade and industry outlets covering the agency’s announcement. (beefmagazine.com)

There has also been practical reaction from the profession. AAHA’s recall notice, published shortly after the January recall, underscored the basic clinical risk: a wound product contaminated with microbes can cause infection, especially if introduced into a sterile site. That point is obvious to veterinarians, but this case shows how quickly a breakdown in sterility can turn into a multi-patient crisis when a product is used in high-risk settings like joints. (aaha.org)

Why it matters: For veterinary professionals, this story goes beyond a single recall. It highlights the exposure practices face when sterile products are used off-label, the importance of tracing lot numbers in ambulatory and hospital settings, and the need to consider product contamination early when clusters of post-treatment infections appear. It also reinforces the value of prompt reporting to FDA’s Center for Veterinary Medicine, because adverse event data can serve as an early warning system for manufacturing-related defects that premarket review may not catch. In equine practice especially, where joint injections and lameness management are routine, this case may prompt tighter internal controls around sourcing, storage, documentation, and post-procedure surveillance. (fda.gov)

What to watch: The next steps are likely to be publication or broader circulation of the warning letters, company responses, and any FDA follow-up on corrective actions at the distributor and manufacturer level. Practices should also watch for whether this incident leads to wider discussion about sterile veterinary manufacturing oversight, clearer communication around labeled use versus common field use, or new guidance on adverse event reporting and recall response workflows. (fda.gov)